HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO EDDA Healthcare and Technology - Concerns Are on Commercialization

Pre-IPO Insight Lifetech - Insights on Industry, Products and Concerns

Shenzhen Mindray Bio-Medical Electronics (300760.CH) - The Logic Behind Optimism

Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns

China Healthcare Weekly (Sep.24) - VBP on Neuro-Intervention, Payment System Changes, AI in Drug R&D

Pre-IPO MicroPort MedBot - The Core Products, the Business Model and the Concerns

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

<p>After hitting a record high of HK$72.85/share in June, the share price of <a href="https://www.smartkarma.com/entities/microport-scientific-corp" target="_blank" data-smartkarma-citation="entities:4487:1" rel="noopener">Microport Scientific (853 HK) </a>has fallen continuously in the following months, down over 45% by the end of October 8, 2021. This insight mainly analyzed the 2021/1H performance, the business, the concerns and the outlook of MicroPort, including both the favorable and the unfavorable aspects.</p>

After hitting a record high of HK$72.85/share in June, the share price of Microport Scientific (853 HK) has fallen continuously in the following months, down over 45% by the end of October 8, 2021. This insight mainly analyzed the 2021/1H performance, the business, the concerns and the outlook of MicroPort, including both the favorable and the unfavorable aspects.

Shandong Weigao Group Medical Polymer Co (1066 HK)

Beijing Chunlizhengda Medical Instruments (1858 HK)

Beijing Chunlizhengda Medical Instruments

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Shanghai MicroPort MedBot Group (2252 HK)

Microport Scientific (853.HK) - The Favorable and the Unfavorable Aspects